Innate Immunotherapeutics Ltd Share Price Australian S.E.
Equities
AU000000IIL6
Biotechnology & Medical Research
Sales 2022 | 1.98M 1.33M 105M | Sales 2023 | 1.19M 796K 62.68M | Capitalization | 16.49M 11.04M 869M |
---|---|---|---|---|---|
Net income 2022 | -3M -2.01M -158M | Net income 2023 | -6M -4.02M -316M | EV / Sales 2022 | 7.87 x |
Net cash position 2022 | 12.51M 8.37M 659M | Net cash position 2023 | 6.98M 4.67M 368M | EV / Sales 2023 | 7.99 x |
P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-2.64
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.95% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 30/05/00 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 24/09/23 |
Rhiannon Jones
COO | Chief Operating Officer | - | 31/01/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 10/10/13 |
Robert Peach
BRD | Director/Board Member | 68 | 01/09/15 |
Warwick Tong
CHM | Chairman | - | 03/05/18 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |